Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

ClinicalTrials.gov ID: NCT04851964

Public ClinicalTrials.gov record NCT04851964. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis

Study identification

NCT ID
NCT04851964
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
416 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 21, 2021
Primary completion
Sep 22, 2024
Completion
Dec 10, 2024
Last update posted
Jan 26, 2026

2021 – 2024

United States locations

U.S. sites
21
U.S. states
16
U.S. cities
21
Facility City State ZIP Site status
Research Site Birmingham Alabama 35209
Research Site Bakersfield California 93301
Research Site Newport Beach California 92663
Research Site Roseville California 95661
Research Site Walnut Creek California 94598
Research Site Colorado Springs Colorado 80923
Research Site Denver Colorado 80230
Research Site Boca Raton Florida 33487
Research Site Chicago Illinois 60657
Research Site Baltimore Maryland 21224
Research Site White Marsh Maryland 21162
Research Site Boston Massachusetts 02115
Research Site Columbia Missouri 65212
Research Site New York New York 10003
Research Site Winston-Salem North Carolina 27103
Research Site Oklahoma City Oklahoma 73120
Research Site North Charleston South Carolina 29406
Research Site Dallas Texas 75231
Research Site Norfolk Virginia 23507
Research Site Spokane Washington 99201
Research Site Milwaukee Wisconsin 53228

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 91 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04851964, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 26, 2026 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04851964 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →